MAP2K7 and metastatic melanoma: Twenty-two percent of all unresectable or metastatic melanoma surviving at year 3 are alive at year 5 and beyond.[18] Although not enough long-term follow-up data are available, this also indicates the longevity of benefit of the combination of BRAF with MEK inhibitor and PD-1 blocker.